Artificial intelligence based technologies for improving patient appointment scheduling and inventory management

USPTO granted US Patent 12,597,511 B2 to CDW LLC covering AI-based technologies for patient appointment scheduling and inventory management. The patented system uses natural language processing to interpret verbal patient responses and queries a scheduling database to match appointments based on distance, date, service, and inventory thresholds. The patent includes 15 claims and names inventors Casey Bleeker and Nathan A. Cartwright.

Methods and Devices for Secure Communication with and Operation of an Implant

USPTO granted patent US12598458B2 to Peter Forsell covering methods and devices for secure communication with and operation of an implantable medical device. The patent includes 20 claims directed to an apparatus for powering an implant using an implantable energy source with an energy provider configured to store and deliver burst energy during startup. CPC classifications H04W 12/033 (secure data handling) and G16H 40/67 (implantable medical device management) indicate applications in remote monitoring and secure patient data transmission.

Health management and guidance instruction issuance assistance

The USPTO granted patent US12597515B2 to Koga Software Co., Ltd. on April 7, 2026, covering a health management system that facilitates collaboration between patients, exercise/nutrition specialists, and doctors through networked servers. The system enables automated creation and manual correction of guidance instructions for exercise and nutrition prescriptions.

Benzalkonium Chloride for Treating COVID-19 and Conjunctivitis

USPTO granted patent US12594251B2 to Bausch + Lomb Ireland Limited on April 7, 2026, covering methods of treating COVID-19 (including ocular manifestations) and conjunctivitis using benzalkonium chloride, as well as methods for reducing COVID-19 transmission using the compound. The patent, with inventors Patrick McCormick and Kimberly Millard, contains 40 claims and is classified under CPC codes A61K 31/14, A61P 27/02, and A61P 31/14.

Small molecule compounds for treating lung epithelial and vascular endothelial cell injury

USPTO granted patent US12594282B2 to Guangzhou Cellprotek Pharmaceutical Co., Ltd. on April 7, 2026. The patent covers the use of 5α-androst-3β,5,6β-triol and analogues for treating pulmonary diseases mediated by lung epithelial cell injury and/or vascular endothelial cell injury. The compounds inhibit PFKFB3 expression and reduce vascular endothelial and alveolar epithelial cell injury.

SCYNEXIS patent for triterpenoid antifungals treating Pneumocystis pneumonia

The USPTO issued patent US12594266B2 to SCYNEXIS, INC. on April 7, 2026, covering eufumafungin derivative triterpenoid antifungal compounds and their use in treating or preventing Pneumocystis pneumonia (PCP). The patent includes 16 claims encompassing the compound structures, pharmaceutical compositions, and methods of treatment.

Methods for treating inflammatory skin conditions (minocycline)

USPTO granted Journey Medical Corporation Patent US12594252B2 covering methods of treating inflammatory skin conditions using reduced-dose minocycline compositions. The patent, with 39 claims, names six inventors including Swati Kulkarni and Rajeev Singh Raghuvanshi. The invention relates to administering a pharmaceutical composition comprising a reduced dose of minocycline to achieve effective plasma or interstitial fluid concentrations for treating inflammatory skin conditions.

Patent US12594280B2: Antiviral Compositions for Influenza Treatment

USPTO granted Patent US12594280B2 to Universite Claude Bernard Lyon 1 covering antiviral pharmaceutical compositions containing Etilefrine and Diltiazem for preventing and treating influenza virus infections. The patent includes 10 claims and covers the use of these compounds in veterinary and pharmaceutical compositions.

Mitochondria-targeted atovagone compounds and methods for antitumor, antimicrobial, and antimalarial treatment

USPTO granted Patent US12594283B2 to The Medical College of Wisconsin, Inc. covering mitochondria-targeted Atovaquone compounds (Mito-ATO) and methods of using such compounds for antitumor, antimicrobial, and antimalarial treatment. The patent contains 22 claims and was filed on October 26, 2020.

Cambridge Cognition Patent - Combination Therapy for Schizophrenia

The USPTO granted Patent US12594270B2 to Cambridge Cognition Limited on April 7, 2026. The patent covers a combined therapy comprising alpha-7 nicotinic acetylcholine receptor activators with 5-HT3 receptor inhibitory activity combined with 5-HT3 receptor activators for treating schizophrenic disorders. The patent contains 21 claims and names Kiri Granger and Jennifer Barnett as inventors.